Campbell Soup Co. (CPB) Stock Price Today
Aura AI Summary
Key Stats
- $6.34BMarket Cap
- 9,842,990Volume
- Consumer StaplesSector
- $31.6652W High
- $18.9052W Low
- 99 DaysTypical Hold Time
- $13.40BEnterprise Value
- 4.7%Div Yield
- 100% Sell | 0% BuyTrading Activity
Track Campbell Soup Co. (CPB) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Campbell Soup Co. has traded between a low of $18.9 and a high of $31.66, highlighting its annual price range. Buy and sell Campbell Soup Co. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Most Recent News
Fortrea and Omico partner to accelerate biomarker-led cancer drug trials in Australia
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...

Fortrea and Omico partner to speed biomarker-based cancer drug trials in Australia
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...

Fortrea and Omico partner to accelerate biomarker-driven cancer drug trials in Australia
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.